Trends in treatment of Peyronie's disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database.

Abstract

Treatments for Peyronie’s Disease (PD) include oral medications, intralesional injections and surgery. Collagenase Clostridium histolyticum (CCh) is the only FDA approved treatment for PD. We sought to examine current trends in treatment of PD across the United States. Using data in the MarketScan Database, we conducted a retrospective study of men with PD in the United States. Cases were identified by ICD-9 and 10 codes, and treatments were identified using NDC and CPT codes. Treatment rates were analyzed using linear regression model, and a cox proportional hazard function test was performed for time-to-treatment analysis. About 27.8% of men with PD were treated within a year of diagnosis. Annual treatment rate increased from 23.2% to 35.4% and intralesional injection was the most used treatment. Over the study period, percentage of men receiving treatment with oral medication increased from 0.66% to 20.5%, while use of intralesional injection and surgery decreased. Increased odds of treatment were observed in men 45–54 years (odds ratio [OR] 1.35; 95% confidence interval [CI], 1.21–1.50; p=0) and in the southern region (OR 1.48; 95% CI, 1.39–1.56; p=0). Trends in treatment of PD have changed over time. Intralesional injection remains the most used treatment option for men with PD.